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Abstract 
Background: The relative contribution of demographic, lifestyle and medication factors to the 
association between affective disorders and cardiometabolic diseases is poorly understood.  
Methods:  Cross-sectional study of 145,991 UK Biobank participants: multivariate analyses of 
associations between features of depression or bipolar disorder and five cardiometabolic outcomes, 
adjusting for confounding factors. 
Results: There were significant associations between mood disorder features and ‘any cardiovascular 
disease’ (depression OR=1.15, 95%CI=1.12-1.18; bipolar OR=1.28, 95%CI=1.14-1.43) and with 
hypertension (depression OR=1.15, 95%CI=1.12–1.1; bipolar OR=1.26, 95%CI=1.12-1.42).  Individuals 
with features of mood disorder taking psychotropic medication were significantly more likely than 
controls to report MI (depression OR=1.47, 95%CI=1.24-1.73; bipolar OR=2.23, 95%CI=1.53–3.57) and 
stroke (depression OR=2.46, 95%CI=2.10-2.80; bipolar OR=2.31, 95%CI=1.39–3.85).  
Conclusion: Associations between features of depression or bipolar disorder and cardiovascular 
diseases outcomes were statistically independent of demographic, lifestyle and medication confounders. 
Psychotropic medication may also be a risk factor for cardiometabolic disease in individuals without a 
clear history of mood disorder. 
Keywords 
Depression, bipolar disorder, cardiovascular disease, diabetes, stroke, psychotropic medication. 
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Background 
Bipolar disorder and major depression are common affective disorders, affecting approximately 2% (1) 
and 16% (2) of the population, respectively. In addition to significant psychiatric morbidity, they also 
impact adversely on social and occupational functioning, quality of life and physical health (3-8), and 
often co-exist with cardiovascular and metabolic diseases (9).  Specifically, both bipolar disorder and 
major depression are associated with coronary heart disease, stroke and peripheral arterial disease and 
there is evidence that these relationships are bidirectional (9-14).   
Although psychotropic medications alter cardiovascular risk profiles (through weight gain, hypertension, 
dyslipidaemia and glucose dysregulation), their use is also associated with a range of demographic and 
lifestyle factors, including social deprivation, smoking and alcohol use (15).  To date, there has been no 
large-scale population-based study in the UK which has assessed associations between a lifetime history 
of depressive or bipolar features and adverse cardiometabolic outcomes while also taking account of a 
wide range of potential confounding factors, including psychotropic medications.   
Beyond the UK, there have been a number of large-scale reports assessing the association between 
mood disorders and cardiometabolic disease, including the National Comorbidity Study Replication (2) 
and the World Mental Health Survey (7).  Although very informative, these studies did not assess the 
wide range of covariates we have been able to include in our analyses. 
The landmark UK Biobank cohort (16), comprising over half a million adults in middle age, represents a 
unique opportunity to explore these associations at a population level (both cross-sectionally and 
prospectively) and has the potential to inform future mechanistic studies and the development of 
population-level interventions.   
Here we assess relationships between five cardiometabolic diseases (myocardial infarction (MI), angina, 
hypertension, diabetes and stroke) and lifetime features of affective disorder (bipolar disorder and 
major depression) within UK Biobank, taking account of demographic,lifestyle and psychotropic 
medication factors. In additional sub-analyses we also assess the effect of current psychotropic 
medication and mood group status on cardiometabolic disease. 
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Methods 
 
Data source  
UK Biobank is a large, prospective cohort of more than 500,000 residents of the United Kingdom, aged 
between 40 and 70years (17). It is one of the largest resources worldwide for studying the genetic, 
environmental, medication and lifestyle factors that cause or prevent disease in middle and older age. 
Recruitment was undertaken over a four year period, from 2006 to 2010.  
In the final two years of UK Biobank recruitment, 172,751 participants were assessed in detail with 
respect to lifetime features of bipolar disorder and major depression.  Eligibility for inclusion in our 
study was restricted to the 145,991 participants who provided complete data on lifetime features of 
mood disorder and complete data on self-reported cardiometabolic disease status (3). 
 
Data collection and ethical approval 
 
Participants attended one of 22 assessment centres located across Great Britain. They completed a 
touchscreen questionnaire which collected information on demographics (including age, sex, ethnicity 
and postcode), health-related behaviours (including smoking status and alcohol consumption), and a 
self-report of physician-diagnosed medical conditions, including diabetes, hypertension, myocardial 
infarction, angina and stroke.  Current medication was recorded with assistance from a member of 
trained clinic staff, who also used standard operating procedures to measure height and weight for 
body mass index (BMI) calculation.  
This study was conducted under generic approval from the NHS National Research Ethics Service 
(approval letter dated 17th June 2011, Ref 11/NW/0382) and full written informed consent was gained 
from participants at the point of data collection. 
Definitions 
Criteria for a lifetime history of clinically-significant features of bipolar disorder or depression were 
based on responses to questions within the baseline touchscreen questionnaire (Appendix 1, Appendix 
2).  Although not diagnostic of bipolar disorder or major depressive disorder, these questions were 
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similar to questions assessing mood disorders within structured diagnostic assessment instruments. To 
some extent the validity of these questions have been supported internally within this dataset by 
comparisons of gender distribution, socioeconomic status, self-reported health rating, current 
depressive symptoms and smoking status (17).  For the purposes of this study, participants were 
categorised into three groups (Figure 1): those with a positive lifetime history of bipolar disorder 
features, those with features of major depression and a control group(17, 19). ‘Any cardiovascular 
disease’ was defined as the self-report of a previous physician diagnosis of hypertension, MI, angina 
and/or stroke. Diabetes was also defined by self-report. BMI was determined though anthropometric 
measurements carried out at the assessment centre and categorised into underweight (<18.5 kg/m2), 
normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), class I obese (30.0-34.9 kg/m2), class II 
obese (35.0-39.9 kg/m2) and class III obese (≥40 kg/m2)(20).Smoking status, frequency of alcohol 
consumption and ethnic group were self-reported on the touchscreen questionnaire. Smoking status 
was classified as ‘current smoker’, ‘previous smoker’ or ‘never smoked’ and alcohol use was classified as 
‘daily/almost daily’, ‘3-4 times per week’, ‘1-2 times per week’, ‘1-3 times/month’, ‘special occasions 
only’ or ‘never’.  Ethnicity was categorised as: ‘white’, ‘mixed’, ‘Asian/Asian British’, ‘black/black British’, 
‘Chinese’, and ‘other’. The Townsend deprivation index - an area-based measure of socioeconomic 
status derived from information collected in the census on car ownership, overcrowding, owner-
occupation and unemployment - includes both positive and negative values, with positive values 
indicating higher levels of deprivation(20). Townsend scores were divided into quintiles (within the 
study population) to facilitate comparisons. The use of current medication (including psychotropics) was 
self-reported by participants and a comprehensive list of commonly used psychotropics was identified 
(Appendix 3). Participants were classified as using psychotropic medication if they reported currently 
taking any of these medications.  
Statistical analyses 
Differences in baseline characteristics between the three groups (control, depressive features and 
bipolar features) were analysed using the chi-squared test for categorical data, and the chi-squared test 
for trend for ordinal data.We used separate logistic regression models to examine the associations 
between mood group (independent variable) and cardiometabolic disease categories (‘any 
cardiovascular disease’ (not including diabetes), diabetes, hypertension, myocardial infarction, angina 
or stroke) (dependent variable),with controls as the referent group.  Models were initially adjusted for 
age, sex, socioeconomic deprivation and ethnicity (the partially adjusted model) and then repeated 
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including additional covariates: smoking status, frequency of alcohol use, BMI and the use of 
psychotropic medication (fully adjusted model). Interaction tests for sex were undertaken and sub-
group analyses carried out as appropriate.  
 
In order to explore the relative contribution of psychotropic medication to cardiometabolic risk across 
the mood spectrum, we carried out a sub analysis to assess the effect of current psychotropic 
medication and mood group status on cardiometabolic disease across the mood spectrum. Six groups 
were created: individuals with no mood disorder features and not currently taking psychotropic 
medication (our referent group); individuals with no mood disorder features but currently taking one or 
more psychotropic medications; individuals with depressive features not currently taking psychotropic 
medication; individuals with depressive features currently taking one or more psychotropic medications; 
individuals with features of bipolar disorder not currently taking any psychotropic medication; and 
individuals with features of bipolar disorder currently taking psychotropic medication.  
Differences in cardiometabolic outcomes between different mood and medication status groups were 
reported as prevalences and then analysed using the chi-squared test for categorical data. We again 
used separate logistic regression models to examine associations between medication and mood 
disorder group with cardiometabolic disease (diabetes, myocardial infarction, angina, hypertension or 
stroke).  As noted above, controls who were not currently taking psychotropic medication were chosen 
as the most appropriate referent group.  These models were adjusted for age, sex, socio-economic 
deprivation and ethnicity, smoking, alcohol and BMI. 
 
All statistical analyses were performed using Stata version 12.1 (StataCorp, College Station, Texas). 
Statistical significance was defined conservatively as p<0.001. 
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Results  
Group characteristics: bipolar features, depression features and controls 
A total of 172,751 UK Biobank participants were assessed at baseline with respect to lifetime history of 
depressive and bipolar features.  Of these, complete data on mood disorder features and 
cardiometabolic disease status were available for 145,991 (84.5%).  From this sample, according to our 
criteria within Figure 1, 1,557 (1.06%) had features of bipolar disorder, 30,991 (21.23%) had features of 
major depression and 113,447 (77.71%) had no significant features of mood disorder (controls) (Table 
1). 
 
Participants with features of bipolar disorder were younger and more likely to be female (Table 1).  
Current smoking was most common in the bipolar features group (21.3%), followed by the depressive 
features group (12.7%) and then the non-mood-disordered control group (8.8%) (Table 1).  The 
proportions of different levels of socioeconomic deprivation were mixed between the groups, but of 
note was that 34.6% of the bipolar features group were in the most deprived quintile, compared to 
22.4% for the depressive features group, and 19.2% for the control group.  White ethnicity was most 
common in the depressive features group and least common in the bipolar features group (Table 1).  
Patterns of alcohol use were similar between groups and obesity was more common in both the 
depressive features and bipolar features groups compared to controls.  Rates of current psychotropic 
medication use were highest in the groups with bipolar (32.1%) and depressive (20.6%) features and 
lowest within the control group (3.4%).   
Prevalence of Cardiometabolic Disease 
The prevalence of ‘any cardiovascular disease’ was highest in the bipolar features group (34.5%), 
followed by the depressive features group (30.6%) and lowest in the control group (28.7%) (Table 1).  
Similar patterns were observed for hypertension, myocardial infarction, angina and stroke.  
Cardiometabolic disease frequencies were also calculated for men and women. Men had consistently 
higher rates of all cardiometabolic diseases and, in general, rates of cardiometabolic disease were 
highest in the bipolar features group, followed by the depressive features group and the control group 
(Table 1).  
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Partially adjusted model 
On multivariate logistic regression (adjusting for age, sex, socio-economic deprivation and ethnicity) 
odds ratios (OR) for all cardiometabolic outcomes were significantly increased in the depressive 
features and the bipolar features group relative to controls (all p<0.001, Table 2).  In general, the odds 
of each cardiometabolic outcome, as well as the odds of having ‘any cardiovascular illness’, increased 
across the two mood groups, in the depressive features group and the bipolar features group (Table 2). 
It should be noted, however, that findings for the bipolar features group with respect to diabetes and 
stroke were not statistically significant.  
The highest odds ratios in the partially adjusted model for the combined male and female group were 
for MI (OR=1.90, p=0.001, 95%CI 1.44-2.51) and angina (OR=1.69, p=0.001, 95%CI 1.30-2.19) within the 
bipolar features group relative to controls, and for diabetes (OR=1.29, p<0.001, 95%CI 1.22-1.37) in the 
depressive features group relative to controls (Table 2).  
There was a significant interaction between mood disorder and sex in predicting risk of having ‘any 
cardiovascular illness’ (p<0.001) and sub-group analyses by sex were subsequently carried out.  Men 
with bipolar features had elevated odds ratios for myocardial infarction (2.02, 95%CI 1.50-2.72). Odds 
ratio for MI in women was not significantly elevated in the partially adjusted group (1.37 (0.65, 2.92) 
p=0.409). Women with bipolar features had slightly higher odds ratios for any cardiovascular disease 
(1.55 95%CI1.32-1.83 in women vs. 1.46 95%CI 1.25-1.69 in men) and for hypertension (1.46 95%CI 
1.24, 1.73 in women vs. 1.42 95%CI 1.22-1.66 in men) (Table 2). 
The odds ratios for specific conditions within the depressive features group were broadly similar for 
men and women.  For angina in men this was OR=1.54 (95% CI = 1.40, 1.69) and OR=1.43 (95%CI = 1.27, 
1.61) for women.  Similarly, for diabetes the OR for men was 1.32 (95%CI = 1.23, 1.44) and for women 
the OR was 1.25 (95%CI = 1.15, 1.36).  In women with depressive features, the odds ratio for stroke was 
1.70 (95%CI = 1.47, 1.97) compared to 1.53 (95%CI = 1.33, 1.76) for men. 
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Fully adjusted model 
On additional adjustment for smoking status, frequency of alcohol consumption, BMI and the use of 
psychotropic medication, the risk of having ‘any cardiovascular illness’ remained significantly elevated 
in both the depressive (OR=1.15 p<0.001, 95%CI 1.12–1.19) and the bipolar features groups (OR=1.28 
p<0.001, 95%CI 1.14–1.43) (Table 2).  This pattern was also largely present in a subgroup analysis by sex 
(Table 2). In the fully adjusted model, odds ratios for hypertension and myocardial infarction were also 
significantly elevated in the combined male and female groups (hypertension: depression: OR=1.15 
p<0.001, 95%CI 1.12–1.13, bipolar: OR=1.26, p<0.001, 95%CI 1.12–1.42) (myocardial infarction: 
depression: OR=1.18, p<0.001, 95%CI 1.08–1.30) (Table 2).  
Differences in odds ratios for angina and stroke within the fully adjusted, combined group analyses 
were not statistically significant. There were, however, significant elevations in odds of cardiovascular 
conditions within the depressive features group, most notably for stroke (OR=1.26, p<0.01, 95%CI 1.13-
1.40) (Table 2). Associations with diabetes were not significant in the fully adjusted model in either the 
depressive features or bipolar features groups. Odds ratios were reduced by approximately a quarter 
for many of the outcome measures upon the additional adjustment for BMI, smoking, alcohol 
consumption and psychotropic medication.  
Current use of any psychotropic medication 
We carried out a sub-analysis to assess the contribution of current psychotropic medication use to 
cardiometabolic risk across the mood spectrum (from controls through depression and bipolar).  
109,577 individuals without features of mood disorder who were not taking psychotropic medication 
were identified as a control group (Table 3). There were 3,867 individuals who did not meet the criteria 
for depressive or bipolar features but who reported taking one or more psychotropic medications 
(Table 3). Although the indication for these medications was not known, this group displayed higher 
prevalences of all cardiometabolic diseases compared to controls. Of particular note were elevated 
rates of diabetes (8.97%), angina (5.87%), hypertension (36.07%) and stroke (3.98%) (Table 3). 
Compared to the control group, individuals with depressive features who reported no current 
psychotropic use showed similar rates of diabetes, myocardial infarction, angina, hypertension and 
stroke and those with depressive features taking psychotropic medication had higher rates of all 
cardiometabolic diseases, with rates of diabetes (8.31%) and MI (3.52%) notably higher than controls 
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(Table 3). It should be noted however that, with the exception of MI, rates of cardiometabolic disease in 
this group were not significantly elevated relative to controls currently on psychotropic medication.  
Rates of cardiometabolic disease in individuals with bipolar features but who were not taking 
psychotropic medication (n=1057) were elevated compared to controls. Rates of diabetes (5.68%), MI 
(2.84%), angina (3.69%), hypertension (30.18%) and stroke (1.70%) in this group were all higher than 
controls (Table 3).Cardiometabolic diseases were most common for individuals with bipolar features 
who were also taking psychotropic medication (diabetes (9.60%), MI (5.00%) and stroke (3.20%)) (Table 
3).  
Fully adjusted medication analyses  
 
To assess the relative contribution of current psychotropic medication use in cardiometabolic disease 
across the mood spectrum we carried out a multivariate logistic regression adjusting for age, sex, 
socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI (Table 
4, Figures 2a-2e).  In general, odds ratios for most cardiometabolic diseases remained significantly 
elevated in each of the mood and medication groups relative to controls (Table 4 and figures 2a-2e).  
Exceptions were for diabetes in the depressive features group not taking psychotropic medication, the 
bipolar features group not taking psychotropic medication, and the bipolar group currently taking 
psychotropic medication. Increases in odds ratios in the bipolar features not on psychotropic 
medication group were also not significantly elevated for angina (OR, 1.58 95%CI 1.22, 2.06, p < 0.001) 
and stroke (OR 1.70, 95%CI 1.20, 2.41, p = 0.003). 
Furthermore, odds ratios for angina and stroke were not significantly elevated for both the bipolar 
features groups (those currently not taking psychotropic medication, as well as those taking 
psychotropic medication) (Table 4, Figures 2a-2e).  
In general, however, the odds of reporting a history of an adverse cardiometabolic outcome were 
associated with both psychotropic medication use and with mood disorder (Table 4, figures 2a-2e) and 
the size of these associations increased with mood disorder severity (from depression to bipolar).
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Discussion 
We found that in a very large population sample of adults with lifetime features of depression and 
bipolar disorder, there was an increased risk of comorbid cardiovascular disorders, even after adjusting 
for a wide range of confounding factors. In general, these associations were more pronounced for 
individuals withfeatures of bipolar disorder than for features of depression. Perhaps unsurprisingly, we 
also identified an association between current use of psychotropic medication and risk of 
cardiometabolic disease in individuals with a history of depressive and bipolar features. It is, however 
notable that this association also occurred in individuals with no definite history of mood disorder who 
were currently taking psychotropic medication. 
Both the bipolar features and depressive features groups had significantly higher odds ratios for ‘any 
cardiovascular disease’ relative to controls, within partially and fully adjusted models. Given the broad 
range of common confounding variables that were adjusted for, this suggests an independent 
association between mood disorder and cardiometabolic diseases.  
Within the partially adjusted (for age, sex, deprivation, ethnicity) versus fully adjusted models 
(additionally adjusted for BMI, smoking status, alcohol consumption and psychotropic medication), 
odds ratios for ‘any cardiovascular disease’ fell from 1.29 (partial) to 1.15 (full) within the depressive 
features group and from 1.50 (partial) to 1.28 (full) in the bipolar features group. Although depression 
has been considered a risk factor for cardiovascular disease for some time (21), there has been debate 
about the relative contribution of lifestyle factors for this group of patients. We have been able to 
control for some of these lifestyle factors. 
Limitations 
The strengths of this study include the general population design, breadth of coverage of confounding 
factors and the very large sample size.However, several limitations are acknowledged. Cardiometabolic 
disorders previously diagnosed by a physician were self-reported by the participants. Similarly, mood 
disorder features were self-reported, rather than assessed using a formal diagnostic interview, although 
a structured approach was used (Figure 1).  Psychiatric diagnoses based on formal interviews were 
notpracticalwithin UK Biobank, so we tooka pragmatic approach to mood disorder groupings. It is 
possible that our criteria for mood disorder are less stringent than formal diagnostic criteria.  
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It should be noted, however, that we are reporting features of mood disorders at a population level, 
rather than formal clinical diagnoses and we were unable to validate diagnoses due to lack of 
availability of definitive diagnostic information.  This has implications in terms of the likely sensitivity 
and specificity of our groupings, which are based on self-report.Linkage to routine hospital and general 
practice health records will be available in the future and will allow validation of our groupings.   
There is however some evidence for the validity of these groupings using internal variables (21), for 
example, the sex distributions of approximately 1:1 for bipolar disorder and approximately 2:1 (women: 
men) for depression are consistent with a large body of epidemiological research on lifetime rates of 
mood disorder in men and women (22, 23).  Furthermore, the lifetime prevalence rates for bipolar 
disorder (1.1%) and recurrent major depressive disorder (21.2%) are consistent with other population-
based lifetime estimates (17).  In the future, linkage of UK Biobank participants to routine health 
records will be possible and will help to address some of these limitations.  
Although we are reasonably confident that members of the control group did not have significant 
features of depression or bipolar disorder, it should be noted that a proportion may have fulfilled 
criteria for other mental illnesses, such as anxiety disorder or, less likely, schizophrenia, both of which 
have been associated with poor cardiometabolic health (24)(25)(26). 
There are also limitations with our broad definition of “current psychotropic medication use”, which 
groups together different classes of medication.  In a sub-analysis of individuals on psychotropic 
monotherapy, we found that SSRIs, other antidepressants and sedatives/hypnotics were all associated 
with greater risk of MI relative to psychotropic-free controls (SSRIs OR 1.82, 95%CI 1.51-2.21; other 
antidepressants OR 1.50, 95%CI 1.20-1.87; and sedatives/hypnotics OR 2.53, 95%CI 1.76-3.66).  It is 
therefore possible that adverse cardiovascular outcomes in depressive disorders are not limited to the 
use of antipsychotics but may also be a consequence of other classes of psychotropic medications. 
 
It is also the case that a relatively low proportion of the mood disorders features groups reported taking 
psychotropic medication (bipolar features 32.1%, depressive features 20.6% and controls 3.4%) but, as 
noted above, the focus in this study was not clinically-diagnosed mood disordered groups but rather 
lifetime features of mood disorder at a population level. Compliance with medication is a major issue in 
the management of mental illness.  
According to some estimates up to 50% of patients prescribed psychotropic medication do not comply 
with their proposed medication (27-29).  Although compliance with physical medication may be slightly 
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better than this (30), it is likely that the factors which cause poor compliance with psychotropic 
medication may also lead to poor compliance with cardiovascular medications in this group.  This might 
explain the proportionately worse cardiovascular outcomes in a less compliant mood disordered group 
compared to a more compliant non-mood disordered group. Due to the level of information on 
medication status which was collected at baseline, we were unable to assess the impact of duration of 
exposure to psychotropic medication on adverse cardiometabolic outcomes. 
We included a range of possible confounding variables in the regression models but were unable to 
control for physical activity. The available data on physical activity was not collected in terms of 
standardised measures.  Unfortunately, it was not possible to create a standardised measure, such as 
the Metabolic Equivalent of Task (MET).Similarly, we were unable to adjust for the potential 
confounding effects of diet. When considering appropriate variables to include as confounding variables, 
it is important to note that there is uncertainty as to the extent that these variables might represent 
confounders or mediators. For example, obesity may represent an important component of the 
pathophysiology for depression, bipolar disorder and coronary heart disease. A prospective cohort 
study is required to address these concerns and is planned as part of future work in this cohort.  
Our analyses did not assess the additive effects of sociodemographic and lifestyle factors. Rather, given 
the large number of confounding factors involved, we took a broad approach, focussing on 
cardiovascular outcomes after partial and full adjustment for confounders. 
 
 
Severity of mood disorder may have contributed to the associations we observed. We therefore 
conducted an additional analysis of the impact of illness severity on the cardiovascular disease 
outcomes. The depressive features group were divided into those who had a history of a probable 
single episode of major depression, versus those with a history of probable moderate recurrent 
depression and those with probable severe recurrent depression (figure 1). The bipolar group was also 
split into those with features of probable bipolar type one illness and those with features of probable 
bipolar type two illness (figure 1).  In general, individuals in the more severe mood disorder groups had 
higher risk of adverse cardiovascular outcomes.  For the bipolar type one group the OR of ‘any 
cardiovascular illness’ was 1.39 (95%CI 1.23-1.58), for the recurrent severe depression group the OR 
was 1.33 (95%CI 1.18-1.50) and for the bipolar type two group the OR was 1.21 (95%CI 1.09-1.32). 
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Findings in the context of previous work 
Many studies have investigated the association between depressive illness and cardiovascular disease 
and the association is well established (31). Relatively fewer studies have examined the association 
between bipolar disorder and cardiovascular disease. Although reports in the literature support the 
association between bipolar disorder and cardiovascular disease(4)(32)(33)(34), these studies have not 
been able to adjust for the same variety of potential confounding factors as in our study.Relative to 
controls, women with features of bipolar disorder had a greater risk of ‘any cardiovascular disease’ than 
men with bipolar features (OR 1.36 versus 1.19).  This finding may be particularly noteworthy given that 
men are known to have increased rates of cardiovascular disease within the general population. In their 
2013 population study, Crump and colleagues (33) reported increased all-cause mortality for women 
with bipolar disorder compared to men with bipolar disorder (adjusted hazard ratio of 2.13 compared 
to 1.74).  Furthermore, the same study reported higher hazard ratios of death from ischaemic heart 
disease for women with bipolar disorder compared to men with bipolar disorder (2.14 compared to 
1.73).  Our findings add to the evidence that women with bipolar disorder may be disproportionately 
affected by cardiovascular disease.Our findings also highlight other, more specific interactions between 
mood disorder and gender with respect to the association with cardiometabolic disease.  In our fully 
adjusted model for individuals with depressive or bipolar features, men (but not women) had an 
increased risk of MI, and women (but not men) were at higher risk of stroke (Table 2). There are several 
possible explanations for this, including studies which have found that men are more likely to receive a 
diagnosis of MI than women (35) and that stroke is more commonly diagnosed in middle-aged women 
than in men (36).  Differential rates of diagnosis of MI may in part be due to the use of troponin levels 
for diagnosis (troponin concentrations correlate with left ventricular mass (37, 38) which is greater in 
men (39).  The increased risk of stroke in middle-aged women compared to men could be explained by 
several factors, including increased systolic blood pressure, increased total cholesterol and inadequate 
risk factor modification in women (36).   
 
Possible mechanisms 
Our study adds to the literature on the associations and covariates of increased cardiometabolic 
morbidity and mortality in mood disorder. There are numerous possible underlying mechanisms for 
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these associations, for example, shared behavioural factors, inequalities in treatment, shared genetic 
vulnerabilities and shared underlying pathophysiology.  
Individuals with mood disorder may have difficulties in accessing preventative medical interventions as 
well as having higher rates of risky lifestyle factors(40). Such factors include including smoking, physical 
inactivity and reduced compliance with cardiovascular medications (41, 42). Individuals with depression 
tend to exercise less and have lower exercise capacity (52, 53, 54). Furthermore, rates of current 
smoking have also been found to be approximately double in those experiencing depressive symptoms 
compared to non-mood-disordered controls (50)(43). Individuals with depression and bipolar disorder 
are also at increased risk of obesity and the combination of sedentary lifestyle, smoking and obesity 
confers a significant additive risk for cardiovascular disease (50).  Other relevant lifestyle factors include 
increased rates of drug and alcohol use in individuals with mood disorder (44, 45). 
Inflammatory pathways are also likely to be relevant to the overlap between mood disorders and 
cardiometabolic disease.  Proinflammatory cytokines are implicated in atherosclerosis (46, 47) and 
individuals with depression are known to have elevated serum levels of inflammatory markers (47). 
Additionally, a depressed mental state in patients receiving angioplasty has been shown to be positively 
correlated with serological markers of inflammation, furthering the case for a role of inflammation in 
the association between mood disorder and cardiovascular disease(48). 
Oxidative stress is also thought to be relevant when considering potential mechanisms for the 
association. Markers of oxidative stress including superoxide dismutase and malondialdehyde have 
been reported as higher in depressed subjects and have also been shown to reduce upon 
pharmacological treatment of depression(49). 
The role of the hypothalamic pituitary axis (HPA) is also relevant. HPA axis abnormalities are associated 
with a variety of cardiometabolic diseases including ischaemic heart disease, stroke and type 2 
diabetes(50).  Moreover, there is some evidence that individuals with severe depression or bipolar 
disorder may have significantly elevated rates of HPA axis dysfunction(51, 52)(53).  
Endothelial dysfunction should also be considered as a potential underlying mechanism for the 
association between mood disorder and cardiometabolic disease. There are reports in the literature 
that both depression and bipolar disorder (54) are linked to endothelial dysfunction. Endothelial 
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dysfunction has been proposed as a potential cause for a variety of cardiometabolic diseases including 
hypertension, hypercholesterolemia, obesity and type 2 diabetes (54)(55). 
Although both depression and coronary heart disease are known to be influenced by genetic factors 
(56-58), there has been relatively little work investigating shared genetic risk factors between the two 
disorders (57).  Scherrer and colleagues reported on the associations between hypertension and 
coronary heart disease in 6,903 male-male twins from the Vietnam Era Twin Registry (57) and found 
significant genetic correlations between depressive symptoms and both hypertension and coronary 
heart disease(57). In addition, there has been work on a possible genetic link between bipolar disorder 
and type 2 diabetes- one genome wide association study found that bipolar disorder and type 2 
diabetes shared 68 single nucleotide polymorphisms (SNPs) (59).  In our study with respect to diabetes, 
odds ratios for individuals with depression were significantly higher in the partially adjusted model but 
not in the fully adjusted model, perhaps because of the association between diabetes and both obesity 
(60) and psychotropic medications (61, 62). 
It is also appropriate to consider the effect of psychological stress on haemodynamic reactivity and 
systolic blood pressure (63). Our findings that the odds ratios for hypertension were increased in both 
depressive features and bipolar features relative to controls could possibly be related to differences in 
haemodynamic reactivity. Heightened cardiovascular reactivity seen in chronic stress may also be 
associated with the triggering of acute coronary events and the development of atherosclerosis (63).  
The effects of psychotropic medication should also be considered. The metabolic effects of psychotropic 
medications are known to increase cardiometabolic risk by various mechanisms including weight gain 
(64), and impaired glucose tolerance (65).Psychotropic medication (appendix 3) was associated with 
cardiometabolic disease (even in the absence of mood disorder features) and that this effect increased 
across the mood disorder spectrum, from depressive features to features of bipolar disorder.   
Given that our analyses were conducted on the basis of current use of any psychotropic medication, it is 
perhaps noteworthy that adverse cardiometbolic effects may not be limited to antipsychotics. There are 
reports in the literature of other psychotropic medications used in the treatment of mood disorder, 
such as antidepressants, lithium and valproic acid, having adverse metabolic effects(66-68). Our finding 
that psychotropic medication is an important factor in the development of cardiometabolic disease in 
the depressive features and the control group adds weight to this.  
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Future work 
There remain several unanswered questions and opportunities for further research. To date, very few 
studies have tested specific genetic associations between lifestyle-related risk factors for 
cardiometabolic disease and the broad spectrum of mood disorders. There is a need for longitudinal 
and mechanistic studies in this area to better understand causal pathways (69). In addition, further 
mechanistic studies examining genetic and epigenetic factors as well as oxidative stress, endothelial 
dysfunction and HPA axis abnormalities, are essential to better understand the associations between 
mood disorder and cardiometabolic disease.  
Conclusions 
Overall, within a large, representative population cohort of UK adults in middle age, we identified 
associations between lifetime features of mood disorders and cardiovascular diseases which in general 
were more pronounced for features of bipolar disorder than for features of major depression.  These 
findings persisted even after adjusting for several confounding factors, including current psychotropic 
medication use, which also increased risk for cardiometabolic disease in individuals without a clear 
history of mood disorder.  
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Figure 1.Criteria for lifetime features of bipolar disorder and depression. 
 
Bipolar disorder features: 
1.  Features of bipolar disorder, type I:  Ever ‘manic or hyper’ for at least 2 days OR ever ‘irritable/argumentative’ 
for 2 days; plus at least 3 features from ‘more active’, ‘more talkative’, ‘needed less sleep’ and ‘more 
creative/more ideas’;  plus duration of a week or more; plus ‘needed treatment or caused problems at work’. 
2.  Features of bipolar disorder, type II:  Ever ‘manic or hyper’ for at least 2 days OR ever 
‘irritable/argumentative’ for 2 days; plus at least 3 features from ‘more active’, ‘more talkative’, ‘needed less 
sleep’ and ‘more creative/more ideas’;  plus duration of a week or more. 
 
Major depression features: 
1.  Features of single episode major depression:  Ever depressed/down for a whole week; plus at least two 
weeks duration; plus only one episode; plus ever seen a GP or a psychiatrist for ‘nerves, anxiety, depression’ OR 
ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; plus only one 
episode; plus ever seen a GP or a psychiatrist for ‘nerves, anxiety, depression’. 
2.  Features of recurrent major depression (moderate):  Ever depressed/down for a whole week; plus at least 
two weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for ‘nerves, anxiety, 
depression’ OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; 
plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for ‘nerves, anxiety, depression’. 
3.  Features of recurrent major depression (severe):  Ever depressed/down for a whole week; plus at least two 
weeks duration; plus at least two episodes; plus ever seen a psychiatrist for ‘nerves, anxiety, depression’ OR ever 
anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; plus at least two 
episodes; plus ever seen a psychiatrist for ‘nerves, anxiety, depression’. 
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Figure 2a - Logistic regression analysis of diabetes associated with mood disorder and medication status 
 
 
1 
1.5 
2 
2.5 
3 
Odds Ratio 
Depressive no psychotropics Controls no psychotropics Controls + psychotropics Depressive + psychotropics Bipolar no psychotropics Bipolar + psychotropics 
Mood Disorder and Medication Group 
Results adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI 
Figure 2a) Logistic Regression Analysis of Diabetes associated with Mood Disorder and Medication Status 
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 Figure 2b - Logistic regression analysis of MI associated with mood disorder and medication 
status. 
 
 
 
1 
2 
3 
4 
5 
Odds ratio 
Controls no psychotropics Controls + psychotropics Depressive no psychotropics Depressive + psychotropics Bipolar no psychotropics Bipolar + psychotropics 
Mood Disorder and Medication Group 
Results adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI 
Figure 2b) Logistic regression analysis of MI associated with mood disorder and medication status 
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Figure 2c - Logistic regression analysis of angina associated with mood disorder and medication status. 
1 
1.
 
2.
 
3.
Odds Ratio 
Controls no psychotropics Controls + psychotropics Depressive no psychotropics Depressive + psychotropics Bipolar no psychotropics Bipolar + psychotropics 
Mood Disorder and Medication Group 
Results adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI  
Figure 2c)Logistic regression analysis of angina associated with mood disorder and 
medication status. 
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Figure 2d - Logistic regression analysis of hypertension associated with mood disorder and medication 
status. 
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Odds ratio 
Controls no psychotropics Controls + psychotropics Depressive no psychotropics Depressive + psychotropics Bipolar no psychotropics Bipolar + psychotropics 
Mood Disorder and Medication Group 
Results adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI 
Figure 2d) Logistic regression analysis of hypertension associated with mood disorder and medication status 
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Figure 2e - Logistic regression analysis of stroke associated with mood disorder and medication status. 
 
 
 
1 
2 
3 
4 
5 
Odds Ratio 
Controls no psychotropics Controls + psychotropics Depressive no psychotropics Depressive + psychotropics Bipolar no psychotropics Bipolar + psychotropics 
Mood and medication group 
Results adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI 
Figure 2d) Logistic regression analysis of stroke associated with mood disorder and medication status. 
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Table 1 Demographic, lifestyle and clinical characteristics 
 
 Control, N (%) 
 
Depression, N (%) Bipolar, 
N (%) 
P-value
 a
 
Participants, n = 
145,991 
 
Demographic and 
lifestyle characteristics 
 
113,444 (77.7) 30,990 (21.2) 1,557 (1.1)  
Sex     
Female 57,082 (50.3) 20,004 (64.6) 766 (49.2) <0.001 
Male 
 
56,362 (46.7) 10,986 (35.5) 791 (50.8)  
Age (years)     
39-49 25,215 (22.2) 8,027 (25.9) 492 (31.6) <0.001 
50-60 40,012 (35.3) 12,351 (39.9) 624 (40.1)  
61-72 
 
48,217 (42.5) 10,612 (34.3) 441 (28.3)  
BMI category     
Underweight 552 (0.5) 159 (0.5) 15 (1.0) <0.001 
Normal-weight 37,613 (33.2) 9,783 (31.6) 451 (29.0)  
Overweight 48,835 (43.1) 12,578 (40.6) 614 (39.4)  
Class I obese 19,473 (17.2) 5,708 (18.4) 328 (21.1)  
Class II obese 5,186 (4.5) 1,888 (6.1) 108 (6.9)  
Class III obese 
 
1,785 (1.6) 874 (2.8) 41 (2.6)  
Townsend score quintile    
1 (least deprived) 19,541 (17.2) 4,802 (15.5) 169 (10.9) <0.001 
2 23,102 (20.4) 5,781 (18.7) 205 (13.2)  
3 23,659 (20.9) 6,270 (20.2) 260 (16.7)  
4 25,414 (22.4) 7,197 (23.2) 384 (24.7)  
5 (most deprived) 
 
21,728 (19.2) 6,940 (22.4) 539 (34.6)  
Ethnicity     
White 103,786 (91.5) 29,295 (94.5) 1,385 (89.0) <0.001 
Mixed 777 (0.7) 264 (0.9) 25 (1.6)  
Asian/Asian British 3,811 (3.4) 564 (1.8) 65 (4.2)  
Black/Black British 3,248 (2.9) 522 (1.7) 50 (3.2)  
Chinese 471 (0.4) 49 (0.2) 6 (0.4)  
Other 
 
1,351 (1.2) 296 (1.0) 26 (1.7)  
Alcohol consumption     
Daily/Almost Daily 23,377 (21.0) 6,134 (19.8) 318 (20.4) <0.001 
3-4 times/week 26,571 (23.4) 6,588 (21.3) 263 (16.9)  
1-2 times/week 29,107 (25.7) 7,467 (24.1) 337 (21.6)  
30 
 
1-3 times/month 12,317 (10.9) 3,943 (12.7) 196 (12.6)  
Special occasions only 12,737 (11.2) 4,091 (13.2) 231 (14.8)  
Never 
 
8,935 (7.9) 2,767 (8.9) 212 (13.6)  
Smoking status     
Never 65,154 (57.4) 15,647 (50.5) 667 (42.8) <0.001 
Previous 38,320 (33.4) 11,412 (36.8) 559 (35.9)  
Current 
 
9,970 (8.8) 3,931 (12.7) 331 (21.3)  
Psychotropic medication    
No 109,577 (96.6) 24,603 (79.4) 1,057 (67.9) <0.001 
Yes 3,867 (3.4) 6,387 (20.6) 500 (32.1) 
 
 
Clinical Characteristics 
 
    
CVD any     
No 80,854 (71.3) 21,516 (69.4) 1,020 (65.5) <0.001 
Yes 
 
32,590 (28.7) 9,474 (30.6) 537 (34.5)  
Diabetes     
No 107,457 (94.7) 29,260 (94.4) 1,449 (93.1) 0.002 
Yes 
 
5,987 (5.3) 1,730 (5.6) 108 (6.9)  
Hypertension     
No 83,762 (73.8) 23,316 (72.0) 1,073 (68.9)  <0.001 
Yes 
 
29,682 (26.2) 8,674 (28.0) 484 (31.1)  
Myocardial infarction     
No 111,046 (97.9) 30,314 (97.8) 1,502 (96.5) 0.001 
Yes 
 
2,398 (2.1) 6,76 (2.2) 55 (3.5)  
Angina     
No 110,296 (97.2) 29,979 (96.7) 1,494 (96.0) <0.001 
Yes 
 
3,148 (2.8) 1,011 (3.3) 63 (4.1)  
Stroke     
No 111,974 (98.7) 30,428 (98.2) 1,523 (97.8) <0.001 
Yes 
 
1,470 (1.3) 562 (1.8) 34 (2.2)  
 
CVD, cardiovascular disease 
a
χ² tests. 
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Table 2.Logistic regression analysis of cardiometabolic disease associated with mood disorder. 
 Overall Female Male 
 Partially adjusted
a
 
 
Fully adjusted
b
 
 
Partially adjusted
a
 
 
Fully adjusted
b
 
 
Partially adjusted
a
 
 
Fully adjusted
b
 
 
 OR (95% CI) P                   OR (95% CI) P                   OR (95% CI) P                   OR (95% CI) P                   OR (95% CI) P                   OR (95% CI) P                   
CVD any             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.29 (1.25, 1.33) <0.001 1.15 (1.12, 1.19) <0.001 1.21 (1.17, 1.26) <0.001 1.08 (1.03, 1.12) <0.001 1.40 (1.34, 1.46) <0.001 1.26 (1.20, 1.32) <0.001 
Bipolar 
1.50 (1.34, 1.68) <0.001 1.28 (1.14, 1.43) <0.001 1.55 (1.32, 1.83) <0.001 1.36 (1.15, 1.62) <0.001 1.46 (1.25, 1.69) <0.001 1.19 (1.02, 1.40) 0.027 
Diabetes             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.29 (1.22, 1.37) <0.001 1.07 (1.03, 1.13) 0.038 1.25 (1.15, 1.36) <0.001 1.03 (0.94, 1.12) 0.554 1.32 (1.23, 1.44) <0.001 1.10 (1.01, 1.20) 0.023 
Bipolar 1.37 (1.15, 1.67) 0.002 1.01 (0.81, 1.24) 0.960 1.17 (0.82, 1.66) 0.399 0.88 (0.61, 1.28) 0.506 1.48 (1.16, 190) 0.002 1.09 (0.84, 1.41) 0.527 
Hypertension             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.27 (1.23, 1.31) <0.001 1.15 (1.13, 1.18) <0.001 1.19 (1.14, 1.24) <0.001 1.07 (1.03, 1.12) 0.002 1.39 (1.32, 1.45) <0.001 1.27 (1.21, 1.34) <0.001 
Bipolar 1.44 (1.29, 1.61) <0.001 1.26 (1.12, 1.42) <0.001 1.46 (1.24, 1.73) <0.001 1.32 (1.11, 1.57) <0.001 1.42 (1.22, 1.66) <0.001 1.20 (1.03, 1.41) 0.022 
MI             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.38 (1.26, 1.51) <0.001 1.18 (1.08, 1.30) <0.001 1.29 (1.08, 1.55) 0.005 1.05 (0.87, 1.27) 0.580 1.41 (1.27, 1.56) <0.001 1.23 (1.11, 1.37) <0.001 
Bipolar 1.90 (1.44, 2.51) <0.001 1.45 (1.09, 1.92) 0.011 1.37 (0.65, 2.92) 0.409 0.93 (0.43, 2.00) 0.855 2.02 (1.50, 2.72) <0.001 1.59 (1.17, 2.16) 0.003 
Angina             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.49 (1.39, 1.61) <0.001 1.23 (1.14, 1.33) <0.001 1.43 (1.27, 1.61) <0.001 1.17 (1.03, 1.32) 0.018 1.54 (1.40, 1.69) <0.001 1.28 (1.16, 1.41) <0.001 
Bipolar 1.69 (1.30, 2.19) <0.001 1.21 (0.93, 1.58) 0.154 1.17 (1.30, 2.90) 0.008 1.33 (0.84, 2.11) 0.231 1.62 (1.18, 2.22) 0.003 1.17 (0.54, 1.61) 0.351 
Stroke             
Control 1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  1 (Reference)  
Depression 1.61 (1.46, 1.78) <0.001 1.26 (1.13, 1.40) <0.001 1.70 (1.47, 1.97) <0.001 1.38 (1.18, 1.61) <0.001 1.53 (1.33, 1.76) <0.001 1.15 (1.00, 1.34) 0.058 
Bipolar 1.80 (1.27, 2.54) 0.001 1.17 (0.82, 1.67) 0.373 2.73 (1.69, 4.41) <0.001 1.85 (1.14, 3.02) 0.013 1.29 (0.78, 2.13) 0.317 0.81 (0.48, 1.34) 0.317 
 
CI; Confidence Interval, CVD, cardiovascular disease; MI, Myocardial Infarction; OR, Odds Ratio 
a
partially adjusted; age, sex, deprivation and ethnicity 
b
fully adjusted; age, sex, deprivation, ethnicity, BMI, smoking status, alcohol consumption and psychotropic medication. 
32 
 
33 
 
Table 3.Cardiometabolic disease in mood and medication groups 
 
 
Mood Group  Diabetes  
(n, %) 
MI  
 (n, %) 
Angina  
 (n, %) 
Hypertension  
 (n, %) 
Stroke 
 (n, %) 
Controls not on 
psychotropic 
medication  
(N=109,514) 
5,640 (5.15) 2,262 (2.06) 2,921 (2.67) 28,287 (25.81) 1,316 (1.20) 
Controls on 
psychotropic 
medication  
(N=3,867) 
347 (8.97) 136 (3.51) 227 (5.87) 1,395 (36.07) 154 (3.98) 
Depressive 
features not on 
psychotropic 
medication  
(N=24,603) 
1,199 (4.87) 508 (2.06) 690 (2.80) 6,609 (26.86) 370 (1.50) 
Depressive 
features on 
psychotropic 
medication  
(N=6,387) 
531 (8.31) 168 (2.63) 321 (5.03) 2,065 (32.33) 192 (3.01) 
Bipolar features 
not on 
psychotropic 
medication  
(N=1557) 
108(6.94) 55(3.53) 63(4.05) 484(31.09) 34(2.18) 
Bipolar symptoms 
on psychotropic 
medication 
(N=500) 
48 (9.60) 25 (5.00) 24 (4.80) 165 (33.00) 16 (3.20) 
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Appendix 1.  Unique Data Identifier (UDI) codes: 
 
Features of bipolar disorder (type I): 
Either: 4642 Ever manic/hyper for at least 2 days or 4653 Ever irritable/argumentative for at least 2 
days, plus 
At least 3 from 6156.01 (more active), 6156.02 (more talkative), 6156.03 (needed less sleep), and 
6156.04 (more creative/more ideas), plus 
5663 Duration of a week or more, plus 
5674 Needed treatment or caused problems at work 
 
Features of bipolar disorder (type II): 
Either: 4642 Ever manic/hyper for at least 2 days or 4653 Ever irritable/argumentative for at least 2 
days, plus 
At least 3 from 6156.01 (more active), 6156.02 (more talkative), 6156.03 (needed less sleep), and 
6156.04 (more creative/more ideas), plus 
5663 Duration of a week or more 
 
Single (probable) episode of major depression: 
EITHER: 
4598 Ever depressed/down for a whole week, plus 
4609 At least two weeks duration, plus 
4620 Only one episode, plus 
2090 Ever seen a GP or 2100 a psychiatrist for nerves, anxiety, depression 
OR: 
4631 Ever anhedonic (unenthusiasm/uninterest) for a whole week, plus 
5375 At least two weeks, plus 
5386 Only one episode, plus 
2090 Ever seen a GP or 2100 a psychiatrist for nerves, anxiety, depression 
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Probable recurrent major depression (moderate): 
EITHER: 
4598 Ever depressed/down for a whole week, plus 
4609 At least two weeks duration, plus 
4620 At least two episodes, plus 
2090 Ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression 
OR: 
4631 Ever anhedonic (unenthusiasm/uninterest) for a whole week, plus 
5375 At least two weeks, plus 
5386 At least two episodes, plus 
2090 Ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression 
 
Probable recurrent major depression (severe): 
EITHER: 
4598 Ever depressed/down for a whole week, plus 
4609 At least two weeks duration, plus 
4620 At least two episodes, plus 
2100 Ever seen a psychiatrist for nerves, anxiety, depression 
OR: 
4631 Ever anhedonic (unenthusiasm/uninterest) for a whole week, plus 
5375 At least two weeks, plus 
5386 At least two episodes, plus 
2100 Ever seen a psychiatrist for nerves, anxiety, depression 
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Appendix 2 – Questions and answers used to assess mood disorder features 
  
Bipolar Features Questions 
1.     Have you ever had a period of time lasting at least two days when you were feeling so good, 
"high", excited or "hyper" that other people thought you were not your normal self or you were 
so "hyper" that you got into trouble?" (4642) or “Have you ever had a period of time lasting at 
least two days when you were so irritable that you found yourself shouting at people or starting 
fights or arguments? (4653)"  
Select: Yes  No Don’t know Prefer not to answer  
2. Please try to remember a period when you were in a “high” or “irritable” state and select which of 
the following apply 
Select:  
I was more active than usual (6156.01) 
I was more talkative than usual (6156.02) 
I needed less sleep than usual (6156.03) 
I was more creative or had more ideas than usual (6156.04) 
All of the above 
None of the above 
  
3.     What is the longest time period that these "high" or "irritable" periods have lasted? (5663)  
 Select:  
  At least two days, but less than a week  
Less than a week 
A week or more 
Do not know 
Prefer not to answer 
 
4.     How much of a problem have these "high" or "irritable" periods caused you? (5674)  
Select:   
No Problems 
Needed treatment or caused problems with work, relationships, finances, the law or other 
aspects of life. 
Do not know 
Prefer not to answer 
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Depressive Features Questions 
1.     Looking back over your life, have you ever had a time when you were feeling depressed or 
down for at least a whole week? (4598) 
Select:  Yes  No Don’t know Prefer not to answer  
2.     How many weeks was the longest period when you were feeling depressed or down? (4609) 
Participants asked to enter the number of weeks on the touchscreen.  
3. How many periods have you had when you were feeling depressed or down for at least a whole 
week?" 
Participants asked to enter the number of periods on the touchscreen.  
4. Have you ever seen a general practitioner (GP) for nerves, anxiety, tension or depression? (2090) 
or Have you ever seen a psychiatrist for nerves, anxiety, tension or depression? (2100)  
Yes  No Don’t know Prefer not to answer  
Anhedonia: 
1.     Have you ever had a time when you were uninterested in things or unable to enjoy the things 
you used to for at least a whole week? (4631)  
Yes  No Don’t know Prefer not to answer  
  
2.     How many weeks was the longest period when you were uninterested in things or unable to 
enjoy the things you used to?"  
Participants asked to enter the number of weeks on the touchscreen.  
3.     How many periods have you had when you were uninterested in things or unable to enjoy the 
things you used to for at least a whole week?"  
Participants asked to enter the number of periods on the touchscreen.  
4. Have you ever seen a general practitioner (GP) for nerves, anxiety, tension or depression? (2090) 
or Have you ever seen a psychiatrist for nerves, anxiety, tension or depression? (2100) 
Yes  No Don’t know Prefer not to answer  
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Appendix 3 – list of psychotropic medications  
1 Mood stabilisers 
2 Antidepressant-
SSRI 3 Antidepressant - Other 
 
lithium product paroxetine mirtazapine 
Priadel (lithium) 
Seroxat 
(paroxetine) Zispin (mirtazapine) 
Camcolit (lithium) fluoxetine duloxetine 
sodium valproate 
Prozac 
(fluoxetine) Cymbalta (duloxetine) 
Epilim (sodium valproate) citalopram Yentreve (duloxetine)  
Depakote (semisodium 
valproate) 
Cipramil 
(citalopram)  venlafaxine 
valproic acid  escitalopram Efexor (venlafaxine) 
carbamazepine product 
Cipralex 
(escitalopram) amitriptyline 
carbamazepine sertraline Elavil (amitriptyline)  
Tegretol (carbamazepine) Lustral (sertraline)  Tryptizol (amitriptyline) 
Teril (carbamazepine) fluvoxamine Lentizol (amitriptyline)  
Teril retard 
(carbamazepine)  amitriptyline+perphenazine 
Timonil retard 
(carbamazepine)  
Triptafen 
(amitriptyline+perphenazine) 
Epimaz (carbamazepine)  amitriptyline+chlordiazepoxide 
  
Limbitrol 10 
(amitriptyline+chlordiazepoxide) 
  
Limbitrol-5 
(amitriptyline+chlordiazepoxide) 
  phenelzine 
  maoi - phenelzine 
  Nardil (phenelzine) 
  moclobemide 
  Manerix (moclobemide) 
  imipramine 
  Tofranil (imipramine) 
  trimipramine 
  Surmontil (trimipramine) 
  dothiepin 
  dosulepin 
  Prothiaden (dosulepin) 
  Thaden (dosulepin) 
  clomipramine 
  Anafranil (clomipramine) 
  lofepramine 
  Gamanil (lofepramine) 
  Lomont (lofepramine) 
  mianserin 
  Bolvidon (mianserin) 
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  Norval (mianserin) 
 
4 Antipsychotic - 
traditional 
5 Antipsychotic - 
second generation 
6 Sedatives and 
hypnotics 
 
chlorpromazine quetiapine diazepam 
cpz - chlorpromazine 
Seroquel 
(quetiapine)  diazepam product 
Largactil (chlorpromazine)  risperidone 
Valium tablet 
(diazepam) 
haloperidol 
Risperdal 
(risperidone)  
Valium syrup 
(diazepam) 
Haldol (haloperidol) olanzapine 
Valiumsupp 
(diazepam) 
Serenace (haloperidol)  
Zyprexa 
(olanzapine) temazepam 
fluphenazinedecanoate aripiprazole 
Normison 
(temazepam) 
fluphenazine 
Abilify 
(aripiprazole)  
Euhypnos 
(temazepam) 
Modecate (fluphenazine)  amisulpride zopiclone 
Moditen tablet 
(fluphenazine)  
Solian 
(amisulpride) 
Zimovane 
(zopiclone)  
Moditenenanthate 
(fluphenazine) clozapine  zaleplon 
flupentixol Clozaril (clozapine)  Sonata (zaleplon) 
Flupenthixol (flupentixol) 
 
zolpidem 
Depixol (flupentixol) 
 
Stilnoct (zolpidem)  
Fluanxol (flupentixol) 
 
nitrazepam 
zuclopenthixol 
 Mogadon 
(nitrazepam) 
Clopixol (zuclopenthixol)  
 Nitrados 
(nitrazepam) 
loxapine 
 Remnos 
(nitrazepam) 
Loxapac (loxapine) 
 Somnite 
(nitrazepam) 
droperidol 
 Noctesed 
(nitrazepam) 
Droleptan (droperidol) 
 
Surem (nitrazepam) 
trifluoperazine 
 Unisomnia 
(nitrazepam) 
Stelazine (trifluoperazine)  
 
flunitrazepam 
thioridazine 
 Rohypnol 
(flunitrazepam) 
Melleril (thioridazine) 
 
triazolam 
 
 
Halcion (triazolam) 
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